AU2001287898A1 - Pyrazolopyridines and pyrazolopyridazines as antidiabetics - Google Patents

Pyrazolopyridines and pyrazolopyridazines as antidiabetics

Info

Publication number
AU2001287898A1
AU2001287898A1 AU2001287898A AU8789801A AU2001287898A1 AU 2001287898 A1 AU2001287898 A1 AU 2001287898A1 AU 2001287898 A AU2001287898 A AU 2001287898A AU 8789801 A AU8789801 A AU 8789801A AU 2001287898 A1 AU2001287898 A1 AU 2001287898A1
Authority
AU
Australia
Prior art keywords
pyrazolopyridazines
pyrazolopyridines
antidiabetics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001287898A
Inventor
Stephen Garland
David Haigh
Deirde Mary Bernadette Hickey
John Liddle
David Glynn Smith
Robert William Ward
Jason Witherington
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0023361A external-priority patent/GB0023361D0/en
Priority claimed from GB0023358A external-priority patent/GB0023358D0/en
Priority claimed from GB0107391A external-priority patent/GB0107391D0/en
Priority claimed from GB0110671A external-priority patent/GB0110671D0/en
Priority claimed from GB0112799A external-priority patent/GB0112799D0/en
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of AU2001287898A1 publication Critical patent/AU2001287898A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84Nitriles
    • C07D213/85Nitriles in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
AU2001287898A 2000-09-22 2001-09-19 Pyrazolopyridines and pyrazolopyridazines as antidiabetics Abandoned AU2001287898A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
GB0023361A GB0023361D0 (en) 2000-09-22 2000-09-22 Novel compounds
GB0023361 2000-09-22
GB0023358A GB0023358D0 (en) 2000-09-22 2000-09-22 Novel compounds
GB0023358 2000-09-22
GB0107391A GB0107391D0 (en) 2001-03-23 2001-03-23 Novel compounds
GB0107391 2001-03-23
GB0110671A GB0110671D0 (en) 2001-05-01 2001-05-01 Novel compounds
GB0110671 2001-05-01
GB0112799A GB0112799D0 (en) 2001-05-25 2001-05-25 Novel compounds
GB0112799 2001-05-25
PCT/GB2001/004186 WO2002024694A1 (en) 2000-09-22 2001-09-19 Pyrazolopyridines and pyrazolopyridazines as antidiabetics

Publications (1)

Publication Number Publication Date
AU2001287898A1 true AU2001287898A1 (en) 2002-04-02

Family

ID=27515980

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001287898A Abandoned AU2001287898A1 (en) 2000-09-22 2001-09-19 Pyrazolopyridines and pyrazolopyridazines as antidiabetics

Country Status (5)

Country Link
US (2) US7109199B2 (en)
EP (1) EP1319001A1 (en)
JP (1) JP2004509891A (en)
AU (1) AU2001287898A1 (en)
WO (1) WO2002024694A1 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004509891A (en) * 2000-09-22 2004-04-02 スミスクライン ビーチャム パブリック リミテッド カンパニー Pyrazolopyridine and pyrazolopyridazine as antidiabetic drugs
ATE433751T1 (en) 2001-04-30 2009-07-15 Vertex Pharma INHIBITORS OF GSK-3 AND CRYSTAL STRUCTURES OF GSK-3BETA PROTEIN AND PROTEIN COMPLEXES
GB0128287D0 (en) * 2001-11-26 2002-01-16 Smithkline Beecham Plc Novel method and compounds
WO2003068773A1 (en) * 2002-02-12 2003-08-21 Glaxo Group Limited Pyrazolopyridine derivatives
GB0207246D0 (en) * 2002-03-27 2002-05-08 Glaxo Group Ltd Novel compounds
GB0207249D0 (en) * 2002-03-27 2002-05-08 Glaxo Group Ltd Novel compounds
DE60319836T2 (en) * 2002-07-25 2009-05-07 Pfizer Italia S.R.L. Heterocyclic condensed pyrazole derivatives as kinase inhibitors
ES2214976B1 (en) * 2003-03-14 2005-12-16 J. URIACH & CIA S.A. "NEW DERIVATIVES OF PIRAZOLOPIRIDINAS".
ES2214150B1 (en) * 2003-02-27 2005-12-01 J. URIACH & CIA S.A. "NEW DERIVATIVES OF PIRAZOLOPIRIDINAS".
PT1611131E (en) 2003-02-27 2010-12-20 Palau Pharma Sa Pyrazolopyridine derivates
US20050014680A1 (en) * 2003-04-15 2005-01-20 Crabtree Gerald R. Methods and compositions for enhancing neuron growth and survival
WO2004110995A1 (en) 2003-06-17 2004-12-23 Pfizer Limited N-pyrrolidin-3-yl-amide derivatives as serotonin and noradrenaline re-uptake inhibitors
BRPI0411891A (en) 2003-06-27 2006-08-29 Pfizer Prod Inc pyrazol [3,4-b] pyridin-6-ones as gsk-3 inhibitors
DE602004015603D1 (en) * 2003-06-27 2008-09-18 Pfizer Prod Inc PYRAZOLOÄ3,4-BÜPYRIDIN-6-ONE AS GSK-3 INHIBITORS
US20070185152A1 (en) * 2004-03-02 2007-08-09 Smithkline Beecham Corporation Inhibitors of akt activity
US7709645B2 (en) 2004-07-27 2010-05-04 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
US7361764B2 (en) 2004-07-27 2008-04-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
CA2573362A1 (en) * 2004-07-27 2006-02-09 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
US7626021B2 (en) * 2004-07-27 2009-12-01 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
MX2007001126A (en) * 2004-07-27 2007-09-25 Sgx Pharmaceuticals Inc Fused ring heterocycle kinase modulators.
EP1934219A1 (en) 2005-09-16 2008-06-25 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
AU2007219509A1 (en) * 2006-01-18 2007-09-07 Siena Biotech S.P.A Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof
DE102006005180A1 (en) * 2006-02-06 2007-08-09 Merck Patent Gmbh Indazol-heteroaryl derivatives
CL2008000119A1 (en) 2007-01-16 2008-05-16 Wyeth Corp COMPOUNDS DERIVED FROM PIRAZOL, ANTAGONISTS OF THE NICOTINIC ACETILCOLINE RECEIVER; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DISEASES SUCH AS SENILE DEMENTIA, ALZHEIMER AND SCHIZOPHRENIA.
AR067762A1 (en) * 2007-07-31 2009-10-21 Vertex Pharma PROCESS TO PREPARE 5-FLUORO-1H-PIRAZOLO (3,4-B) PIRIDIN-3-AMINA AND DERIVATIVES OF THE SAME
CA2714181C (en) * 2008-02-04 2013-12-24 Mercury Therapeutics, Inc. Ampk modulators
ES2581678T3 (en) * 2009-01-28 2016-09-06 Rigel Pharmaceuticals, Inc. Carboxamide compounds and methods for using them
US8487102B2 (en) * 2010-04-20 2013-07-16 Hoffmann-La Roche Inc. Pyrrazolopyridine compounds as dual NK1/NK3 receptor antagonists
WO2012135631A1 (en) 2011-03-30 2012-10-04 Arrien Pharmaeuticals Llc Substituted 5-(pyrazin-2-yl)-1h-pyrazolo [3, 4-b] pyridine and pyrazolo [3, 4-b] pyridine derivatives as protein kinase inhibitors
KR102129114B1 (en) * 2018-07-26 2020-07-02 주식회사 온코파마텍 A compound having TrkA inhibitory activity, and a pharmaceutical composition for preventing or treating pain containing the compound as an active ingredient
EP3920885A1 (en) 2019-02-08 2021-12-15 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders
CN118126038B (en) * 2024-05-08 2024-07-12 烟台大学 Pyrazolopyridine derivative, and preparation method and application thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2238400A1 (en) 1972-08-04 1974-02-14 Hoechst Ag Basic azo dyes from 3-amino 1H-pyrazolo (3,4-b) pyridines - for use on polyacrylonitrile or acid-modified polyester fibres
US4361568A (en) 1981-04-28 1982-11-30 Sterling Drug Inc. 5-(Pyridinyl)-1H-pyrazolo[3,4-b]pyridin-3-amines and their cardiotonic use
WO1997041854A1 (en) 1996-05-07 1997-11-13 The Trustees Of The University Of Pennsylvania Inhibitors of glycogen synthase kinase-3 and methods for identifying and using the same
JP4783532B2 (en) * 2000-02-05 2011-09-28 バーテックス ファーマシューティカルズ インコーポレイテッド Pyrazole compositions useful as inhibitors of ERK
AU4878601A (en) 2000-04-20 2001-11-07 Mitsubishi Corporation Aromatic amide compounds
JP2004509891A (en) * 2000-09-22 2004-04-02 スミスクライン ビーチャム パブリック リミテッド カンパニー Pyrazolopyridine and pyrazolopyridazine as antidiabetic drugs

Also Published As

Publication number Publication date
WO2002024694A1 (en) 2002-03-28
US20040019052A1 (en) 2004-01-29
EP1319001A1 (en) 2003-06-18
JP2004509891A (en) 2004-04-02
US7109199B2 (en) 2006-09-19
US20060223800A1 (en) 2006-10-05
US7297792B2 (en) 2007-11-20

Similar Documents

Publication Publication Date Title
AU2001287898A1 (en) Pyrazolopyridines and pyrazolopyridazines as antidiabetics
AU2002235128A1 (en) Expression miniarrays and uses thereof
AU2001260327A1 (en) Chair
AU2001213236A1 (en) Mini-cyclone biocollector and concentrator
AU2001264313A1 (en) Pyrazolopyridine compounds and use thereof as drugs
AU2001280599A1 (en) Compounds and methods
AU2001253418A1 (en) Compounds and methods
AU2002219135A1 (en) Substituted 2-anilino-benzimidazoles and the use thereof as NHE-inhibitors
AU2002211717A1 (en) Stresscopins and their uses
AU2001272011A1 (en) Siderophores-producing bifidobacteria thereby and uses thereof
AU2001243394A1 (en) Compounds and methods
AU2001292936A1 (en) Octahydro-indolizines and quinolizines and hexahydro-pyrrolizines
AU2002222485A1 (en) Multi-purpose structure
AU2002213429A1 (en) Antiviral methods and compounds
AU2001261750A1 (en) Laminate and its use
AU2001295185A1 (en) Multiplexing-interleaving and demultiplexing-deinterleaving
AUPQ872300A0 (en) Compounds and methods
AU2001234178A1 (en) Modified bdnf
AU2002227925A1 (en) Human beta-defensin-3
AU2001278951A1 (en) Compounds and methods
AU2001252200A1 (en) Chair
AU4432001A (en) Trityl-type compounds and their use
AU2001252671A1 (en) Pyridobenzodiazine derivatives and processes for the preparation thereof
AU2001252062A1 (en) Steatosis-modulating factors and uses thereof
AUPR099200A0 (en) New formulation